Andre G. Uitterlinden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Recognitions
Andre G. Uitterlinden has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Fernando Rivadeneira
Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
49 shared publications - Mohammad Arfan Ikram
Erasmus MC University Medical Center, Rotterdam, The Netherlands
46 shared publications Albert Hofman
Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands
26 shared publications- Cornelia M. van Duijn
Nuffield Department of Population Health, University of Oxford, Oxford, UK
21 shared publications - Vilmundur Gudnason
Faculty of Medicine, University of Iceland, Reykjavik, Iceland
21 shared publications - Carolina Medina-Gomez
Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
20 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 23 April 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (5) , 1040-1050
Genomic analyses implicate hormonal and metabolic dysregulation in polycystic ovary syndrome
Polycystic ovary syndrome (PCOS) and its underlying features remain poorly understood. In this genetic study ( n = 544,513), we expand the number of genetic loci from 16 to 29, and additionally identify 31 associated plasma proteins. Many risk-increasing loci were associated with later age at menopause, underscoring the reproductive longevity related to an increased oocyte number and/or availability across the lifespan. Hormonal regulation in the etiology of this condition, through metabolic and reproductive features, was emphasized. The proteomic analysis highlighted metabolic biology known to be related to PCOS. A polygenic risk score (PRS) was associated with adverse cardiometabolic outcomes, with differing relevance of testosterone and body mass index in women and men. Finally, while oligo-anovulation and anovulatory infertility are features of PCOS, we observed no impact of PCOS susceptibility on childlessness. We suggest that PCOS susceptibility confers balanced pleiotropic influences on fertility in women, and life-long adverse metabolic consequences in both sexes.
- 23 April 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (5) , 1040-1050
Top Cited PapersOpen AccessGenomic analyses implicate hormonal and metabolic dysregulation in polycystic ovary syndrome
Polycystic ovary syndrome (PCOS) and its underlying features remain poorly understood. In this genetic study ( n = 544,513), we expand the number of genetic loci from 16 to 29, and additionally identify 31 associated plasma proteins. Many risk-increasing loci were associated with later age at menopause, underscoring the reproductive longevity related to an increased oocyte number and/or availability across the lifespan. Hormonal regulation in the etiology of this condition, through metabolic and reproductive features, was emphasized. The proteomic analysis highlighted metabolic biology known to be related to PCOS. A polygenic risk score (PRS) was associated with adverse cardiometabolic outcomes, with differing relevance of testosterone and body mass index in women and men. Finally, while oligo-anovulation and anovulatory infertility are features of PCOS, we observed no impact of PCOS susceptibility on childlessness. We suggest that PCOS susceptibility confers balanced pleiotropic influences on fertility in women, and life-long adverse metabolic consequences in both sexes.
- Open Access
- 17 February 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (4) , e041398
Restricted Versus Genome‐Wide Genetic Risk Scores for Coronary Artery Disease
Background: Genetic risk scores may be useful for analyzing risks for coronary artery disease (CAD). However, comparisons between restricted and genome‐wide scores have been underexplored, particularly for individuals at increased risk by one score but not the other. Here, we compared restricted polygenic risk scores with 181 high‐confidence genetic variants (PRS 181 ) and genome‐wide risk scores that encompass 6.6 million single‐nucleotide polymorphisms (GRS 6.6M ). Methods: Data were from the RS (Rotterdam Study; n=11 001), MESA (Multi‐Ethnic Study of Atherosclerosis; n=2685), and the Sanford Health study (n=25 166). We analyzed score associations with CAD (prevalent and incident), age at onset, and lipid medication use. Combined use of both scores was also examined. Results: There were robust associations with CAD per SD of the scores for men (PRS 181 : hazard ratio [HR], 1.19 [95% CI, 1.13–1.26]; GRS 6.6M : HR, 1.32 [95% CI, 1.26–1.39]) and women (PRS 181 : HR, 1.24 [95% CI, 1.16–1.32]; GRS 6.6M : HR, 1.32 [95% CI, 1.25–1.40]). PRS 181 was more strongly associated with early‐onset CAD in men (β=−0.93 [95% CI, −1.36 to −0.50]) and women (β=−0.76 [95% CI, −1.31 to −0.21]). Both scores correlated with lipid medication use, but the scores were also associated with CAD among nonusers. Individuals at high risk by both scores had the highest risk and the earliest age at onset. Conclusions: PRS 181 and GRS 6.6M appear to identify different subsets of individuals. Use of both scores together may provide better association information on CAD risk and age at onset than each score alone.
- 17 February 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (4) , e041398
Open AccessRestricted Versus Genome‐Wide Genetic Risk Scores for Coronary Artery Disease
Background: Genetic risk scores may be useful for analyzing risks for coronary artery disease (CAD). However, comparisons between restricted and genome‐wide scores have been underexplored, particularly for individuals at increased risk by one score but not the other. Here, we compared restricted polygenic risk scores with 181 high‐confidence genetic variants (PRS 181 ) and genome‐wide risk scores that encompass 6.6 million single‐nucleotide polymorphisms (GRS 6.6M ). Methods: Data were from the RS (Rotterdam Study; n=11 001), MESA (Multi‐Ethnic Study of Atherosclerosis; n=2685), and the Sanford Health study (n=25 166). We analyzed score associations with CAD (prevalent and incident), age at onset, and lipid medication use. Combined use of both scores was also examined. Results: There were robust associations with CAD per SD of the scores for men (PRS 181 : hazard ratio [HR], 1.19 [95% CI, 1.13–1.26]; GRS 6.6M : HR, 1.32 [95% CI, 1.26–1.39]) and women (PRS 181 : HR, 1.24 [95% CI, 1.16–1.32]; GRS 6.6M : HR, 1.32 [95% CI, 1.25–1.40]). PRS 181 was more strongly associated with early‐onset CAD in men (β=−0.93 [95% CI, −1.36 to −0.50]) and women (β=−0.76 [95% CI, −1.31 to −0.21]). Both scores correlated with lipid medication use, but the scores were also associated with CAD among nonusers. Individuals at high risk by both scores had the highest risk and the earliest age at onset. Conclusions: PRS 181 and GRS 6.6M appear to identify different subsets of individuals. Use of both scores together may provide better association information on CAD risk and age at onset than each score alone.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts
Supplemental Table 3 shows the multivariable clinical model, performed in the CCSS Original cohort, to determine treatment factors for stratified GWASs.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts
Supplemental Table 3 shows the multivariable clinical model, performed in the CCSS Original cohort, to determine treatment factors for stratified GWASs.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts
Supplemental Table 1 depicts the definition and timing of dyslipidemia assessments per cohort.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts
Supplemental Table 1 depicts the definition and timing of dyslipidemia assessments per cohort.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts
Supplemental Figure 3 shows an overview of the performed analyses and outcomes.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts
Supplemental Figure 3 shows an overview of the performed analyses and outcomes.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts
Supplemental Table 2 shows the demographic and treatment characteristics of the discovery and replication cohorts, stratified per dyslipidemia status.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts
Supplemental Table 2 shows the demographic and treatment characteristics of the discovery and replication cohorts, stratified per dyslipidemia status.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 4 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts
Supplemental Table 4 shows the top SNP-lipid pairs (LRT <0.01 in SJLIFE) identified through linear regression using continuous lipid traits as endpoints.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 4 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts
Supplemental Table 4 shows the top SNP-lipid pairs (LRT <0.01 in SJLIFE) identified through linear regression using continuous lipid traits as endpoints.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts
Supplemental Figure 2 shows the QQ plot of the initial discovery analysis.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts
Supplemental Figure 2 shows the QQ plot of the initial discovery analysis.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts
Supplemental Figure 1 shows the flowcharts of the CCSS Original, SJLIFE, CCSS Expansion, and DCCSS-LATER cohorts, indicating included and excluded subjects.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Genetic Contribution to Treatment-Related Dyslipidemia in Adult Survivors of Childhood Cancer: Findings from the CCSS, SJLIFE, and DCCSS-LATER Cohorts
Supplemental Figure 1 shows the flowcharts of the CCSS Original, SJLIFE, CCSS Expansion, and DCCSS-LATER cohorts, indicating included and excluded subjects.
- Open Access
- 1 October 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 34 (1) , 175-179
Partitioning knee osteoarthritis genetic variants based on BMI association to improve polygenic risk prediction
- 1 October 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 34 (1) , 175-179
Open AccessPartitioning knee osteoarthritis genetic variants based on BMI association to improve polygenic risk prediction